FDA Clears Lensar’s Adaptive Cataract Treatment System

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Lensar has received 510(k) clearance from the FDA for its next-generation Ally Adaptive Cataract Treatment System, according to a press release.

Ally is the first FDA-approved platform that enables cataract surgeons to perform femtosecond laser-assisted cataract surgery (FLACS) in a single environment, according to the release. The system uses adaptive intelligence to optimize fragmentation patterns and energy parameters as well as automatically determine cataract density.

“Our mission has been to develop a platform where surgeons can seamlessly perform the entire FLACS procedure in a single setting, improve workflow efficiency, and most importantly, help surgeons achieve better results thanks to the advanced technologies of the Ally system”, Nick Curtis, CEO of Lensar, said in the statement.

Lensar expects to ship the first Ally systems in Q3 through a targeted initial launch followed by broad availability in 2023.

Comments are closed.